Hims & Hers Health Rises 2.84% on 76th-Ranked Volume Amid Legal Scrutiny and Collapsed Partnership with Novo Nordisk

Hims & Hers Health (HIMS) closed August 20, 2025, with a 2.84% gain, trading at $X.XX. The stock recorded $1.05 billion in volume, ranking 76th in market activity for the day. Recent developments have intensified scrutiny on the company’s business practices, particularly following the collapse of its partnership with Novo Nordisk and ongoing legal investigations.

Multiple law firms are representing investors in class-action lawsuits alleging Hims misled the market during the period of April 29 to June 23, 2025. The lawsuits claim the company failed to disclose its role in promoting and selling unauthorized versions of Wegovy, a GLP-1 weight-loss drug. These actions allegedly created significant risks to patient safety and triggered Novo Nordisk’s abrupt termination of their collaboration, which had previously been a key growth driver for Hims.

Following the partnership’s dissolution, Hims’ stock plummeted over 34% on June 23. Legal filings suggest the company’s marketing strategies and business model may have been misrepresented to investors. The U.S. Federal Trade Commission is also investigating Hims’ advertising and subscription practices, adding regulatory pressure to the company’s operations.

Investors who purchased shares between April 29 and June 23, 2025, are being urged to participate in the lawsuits ahead of the August 25 deadline to designate a lead plaintiff. Legal experts argue the case highlights broader questions about the sustainability of Hims’ business model and the alignment of its public disclosures with operational realities.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to now delivered moderate returns. The 1-day return was 0.98%, with a total return of 31.52% over 365 days. This indicates the strategy captured some short-term momentum but also reflected market volatility and potential timing risks.